tetano
Editor, Senior Moderator
J Family Med Prim Care
. 2021 Oct;10(10):3561-3567.
doi: 10.4103/jfmpc.jfmpc_1297_20. Epub 2021 Nov 5.
COVID-19 and thrombotic complications-the role of anticoagulants, antiplatelets and thrombolytics
Gaurav Khandelwal[SUP] 1 [/SUP], Avik Ray[SUP] 2 [/SUP], Samdish Sethi[SUP] 3 [/SUP], H K Harikrishnan[SUP] 4 [/SUP], Chaitanya Khandelwal[SUP] 3 [/SUP], Balakrishnan Sadasivam[SUP] 2 [/SUP]
Affiliations
Abstract
Coronavirus disease 2019 (COVID-19) is a global pandemic the world is dealing with currently. Clinical evidences suggest that the patients are predisposed to both venous and arterial thrombotic complications. This is because of severe inflammatory responses, injury to endothelium and activation of platelets leading to increased coagulation. Additionally, individuals who are already receiving antithrombotic drug therapy for various cardiovascular diseases and complications might contract the disease in which case, attention should be given to the choice and duration of the therapy besides close monitoring of biochemical blood parameters. Herein, we review the incidences of thrombotic complications and their outcomes in COVID-19 patients as reported till date, while understanding the prophylactic and therapeutic roles of anticoagulants, antiplatelets and thrombolytics in the management of this severe viral respiratory illness.
Keywords: Anticoagulant; SARS-CoV-2; antiplatelet; coronavirus disease 2019; thrombolytics; thrombosis.
. 2021 Oct;10(10):3561-3567.
doi: 10.4103/jfmpc.jfmpc_1297_20. Epub 2021 Nov 5.
COVID-19 and thrombotic complications-the role of anticoagulants, antiplatelets and thrombolytics
Gaurav Khandelwal[SUP] 1 [/SUP], Avik Ray[SUP] 2 [/SUP], Samdish Sethi[SUP] 3 [/SUP], H K Harikrishnan[SUP] 4 [/SUP], Chaitanya Khandelwal[SUP] 3 [/SUP], Balakrishnan Sadasivam[SUP] 2 [/SUP]
Affiliations
- PMID: 34934647
- PMCID: PMC8653484
- DOI: 10.4103/jfmpc.jfmpc_1297_20
Abstract
Coronavirus disease 2019 (COVID-19) is a global pandemic the world is dealing with currently. Clinical evidences suggest that the patients are predisposed to both venous and arterial thrombotic complications. This is because of severe inflammatory responses, injury to endothelium and activation of platelets leading to increased coagulation. Additionally, individuals who are already receiving antithrombotic drug therapy for various cardiovascular diseases and complications might contract the disease in which case, attention should be given to the choice and duration of the therapy besides close monitoring of biochemical blood parameters. Herein, we review the incidences of thrombotic complications and their outcomes in COVID-19 patients as reported till date, while understanding the prophylactic and therapeutic roles of anticoagulants, antiplatelets and thrombolytics in the management of this severe viral respiratory illness.
Keywords: Anticoagulant; SARS-CoV-2; antiplatelet; coronavirus disease 2019; thrombolytics; thrombosis.